Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?
作者信息
Malek Alexandre E, Dagher Hiba, Hachem Ray, Chaftari Anne M, Raad Issam I
机构信息
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
J Med Virol. 2021 Jul;93(7):4083-4084. doi: 10.1002/jmv.26915. Epub 2021 Mar 14.
Abstract
摘要
相似文献
1
Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?一剂mRNA疫苗对新冠康复者是否足够？
J Med Virol. 2021 Jul;93(7):4083-4084. doi: 10.1002/jmv.26915. Epub 2021 Mar 14.
2
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者两剂 SARS-CoV-2 信使 RNA 疫苗接种的安全性和抗体反应。
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
3
Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.在使用 ChAdOx1 nCOV-19 疫苗进行初级免疫后，BNT162b2 或 mRNA-1273 第二针后医护人员的不良反应率。
Clin Microbiol Infect. 2022 Jun;28(6):885.e1-885.e5. doi: 10.1016/j.cmi.2022.02.010. Epub 2022 Feb 16.
4
COVID-19 Updates: Pfizer-BioNTech COVID-19 vaccine.新冠疫情最新消息：辉瑞-生物科技公司新冠疫苗
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16.
5
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.信使核糖核酸新冠疫苗接种后心肌炎风险的Meta分析
Am J Cardiol. 2022 Mar 15;167:155-157. doi: 10.1016/j.amjcard.2021.12.007. Epub 2022 Jan 19.
6
Mixing vaccines may boost immune responses.混合使用疫苗可能会增强免疫反应。
Science. 2021 Jun 11;372(6547):1138. doi: 10.1126/science.372.6547.1138.
7
COVID-19 vaccine dosing recommendations flowchart.2019冠状病毒病疫苗接种建议流程图。
Med Lett Drugs Ther. 2021 Nov 1;63(1636):e1.
8
Delaying the second dose of covid-19 vaccines.推迟新冠疫苗的第二剂接种。
BMJ. 2021 Mar 18;372:n710. doi: 10.1136/bmj.n710.
9
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
10
Fast Development of High-Quality Vaccines in a Pandemic.大流行期间高质量疫苗的快速研发
Chest. 2021 Jul;160(1):e1-e3. doi: 10.1016/j.chest.2021.03.063. Epub 2021 Apr 20.
引用本文的文献
1
COVID-19 vaccination challenges: A mini-review.COVID-19 疫苗接种挑战：小型综述。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2066425. doi: 10.1080/21645515.2022.2066425. Epub 2022 May 5.
2
MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis.多发性硬化症患者 COVID-19 疫苗接种的 MENACTRIMS 实践指南。
Mult Scler Relat Disord. 2021 Nov;56:103225. doi: 10.1016/j.msard.2021.103225. Epub 2021 Aug 25.
本文引用的文献
1
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.FDA 授权的 mRNA COVID-19 疫苗根据多州医疗系统综合的真实世界证据有效。
Med. 2021 Aug 13;2(8):979-992.e8. doi: 10.1016/j.medj.2021.06.007. Epub 2021 Jun 29.
2
Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.BNT162b2疫苗接种者中SARS-CoV-2感染和新冠肺炎的早期感染率降低情况。
Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7. Epub 2021 Feb 18.
3
Assessment of the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection in an Intense Reexposure Setting.在高强度再暴露环境下评估严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）再感染的风险。
Clin Infect Dis. 2021 Oct 5;73(7):e1830-e1840. doi: 10.1093/cid/ciaa1846.
Zotero 插件